Onconetix, Inc. Operating Expenses
Onconetix, Inc. (ONCO) reported Operating Expenses of $2.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Onconetix, Inc. operating expenses for the quarter ending 2026-06-30 was $2.74M, a 36.35% increase year-over-year.
- Onconetix, Inc. operating expenses for the quarter ending 2026-03-31 was $10.22M, a 18.96% decline year-over-year.
- Onconetix, Inc. operating expenses for the quarter ending 2025-12-31 was $1.53M, a 94.87% decline year-over-year.
- Onconetix, Inc. operating expenses for the quarter ending 2025-09-30 was $2.34M, a 15.02% decline year-over-year.
- Onconetix, Inc. operating expenses for fiscal 2025 was $18.49M, a 67.87% decline from fiscal 2024.
- Onconetix, Inc. operating expenses for fiscal 2024 was $57.54M, a 64.85% increase from fiscal 2023.
- Onconetix, Inc. operating expenses for fiscal 2023 was $34.91M, a 158.93% increase from fiscal 2022.
- Onconetix, Inc. operating expenses for fiscal 2022 was $13.48M, a 294.50% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.74M 10-Q · filed 2026-08-13 | $12.96M 10-Q · filed 2026-08-13 | $14.49M derived: sum of 3 quarters · filed 2026-08-13 | $16.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.22M 10-Q · filed 2026-05-13 | $11.75M derived: sum of 2 quarters · filed 2026-05-13 | $14.09M derived: sum of 3 quarters · filed 2026-05-13 | $16.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $3.87M derived: sum of 2 quarters · filed 2026-03-13 | $5.87M derived: sum of 3 quarters · filed 2026-08-13 | $18.49M 10-K · filed 2026-03-13 |
| 2025-09-30 | $2.34M 10-Q · filed 2025-11-13 | $4.34M derived: sum of 2 quarters · filed 2026-08-13 | $16.96M 10-Q · filed 2025-11-13 | $46.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.01M 10-Q · filed 2026-08-13 | $14.62M 10-Q · filed 2026-08-13 | $44.43M derived: sum of 3 quarters · filed 2026-08-13 | $47.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $12.62M 10-Q · filed 2026-05-13 | $42.42M derived: sum of 2 quarters · filed 2026-05-13 | $45.17M derived: sum of 3 quarters · filed 2026-05-13 | $58.89M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $29.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $32.56M derived: sum of 2 quarters · filed 2026-03-13 | $46.27M derived: sum of 3 quarters · filed 2026-03-13 | $57.54M 10-K · filed 2026-03-13 |
| 2024-09-30 | $2.75M 10-Q · filed 2025-11-13 | $16.47M derived: sum of 2 quarters · filed 2025-11-13 | $27.74M 10-Q · filed 2025-11-13 | $48.66M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $13.72M 10-Q · filed 2025-08-14 | $24.99M 10-Q · filed 2025-08-14 | $45.91M derived: sum of 3 quarters · filed 2025-08-14 | $50.40M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.27M 10-Q · filed 2025-06-12 | $32.19M derived: sum of 2 quarters · filed 2025-06-12 | $36.68M derived: sum of 3 quarters · filed 2025-06-12 | $43.33M derived: sum of 4 quarters · filed 2025-06-12 |
| 2023-12-31 | $20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $25.41M derived: sum of 2 quarters · filed 2025-06-02 | $32.06M derived: sum of 3 quarters · filed 2025-06-02 | $34.91M 10-K · filed 2025-06-02 |
| 2023-09-30 | $4.49M 10-Q · filed 2024-12-10 | $11.14M derived: sum of 2 quarters · filed 2024-12-10 | $13.99M 10-Q · filed 2024-12-10 | $17.23M derived: sum of 4 quarters · filed 2024-12-10 |
| 2023-06-30 | $6.65M 10-Q · filed 2024-08-29 | $9.50M 10-Q · filed 2024-08-29 | $12.74M derived: sum of 3 quarters · filed 2024-08-29 | $16.61M derived: sum of 4 quarters · filed 2024-08-29 |
| 2023-03-31 | $2.85M 10-Q · filed 2024-05-20 | $6.09M derived: sum of 2 quarters · filed 2024-05-20 | $9.96M derived: sum of 3 quarters · filed 2024-05-20 | $14.26M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $7.12M derived: sum of 2 quarters · filed 2024-04-11 | $11.41M derived: sum of 3 quarters · filed 2024-04-11 | $13.48M 10-K · filed 2024-04-11 |
| 2022-09-30 | $3.87M 10-Q · filed 2023-11-17 | $8.16M derived: sum of 2 quarters · filed 2023-11-17 | $10.24M 10-Q · filed 2023-11-17 | $11.44M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | $4.29M 10-Q · filed 2023-10-20 | $6.37M 10-Q · filed 2023-10-20 | $7.57M derived: sum of 3 quarters · filed 2023-10-20 | $8.66M derived: sum of 4 quarters · filed 2023-10-20 |
| 2022-03-31 | $2.07M 10-Q · filed 2023-05-12 | $3.27M derived: sum of 2 quarters · filed 2023-05-12 | $4.37M derived: sum of 3 quarters · filed 2023-05-12 | $5.16M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.30M derived: sum of 2 quarters · filed 2023-03-09 | $3.09M derived: sum of 3 quarters · filed 2023-03-09 | $3.42M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-14 | $1.89M derived: sum of 2 quarters · filed 2022-11-14 | $2.21M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $792.27K 10-Q · filed 2022-08-15 | $1.12M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $325.78K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |